Revolution Medicines Q4 net loss $52.7M, FY2021 net loss $187.1M; RAS pipeline advances

Revolution Medicines, Inc.

2022-FY EPS reported -$2.57 revenue$29,390,000

Cash, cash equivalents and marketable securities $577.1M at Dec 31, 2021 vs $440.7M at Dec 31, 2020.
Total revenue $9.5M Q4 2021 vs $8.8M Q4 2020; FY2021 $29.4M vs $43.0M FY2020 (incl. $8.5M non-cash adjustment).
Net loss $52.7M Q4 2021 vs $34.2M Q4 2020; FY2021 $187.1M vs $108.2M FY2020.
Full year 2022 GAAP net loss guidance $260M-$290M; stock-based comp $35M-$40M.
RMC-4630+sotorasib Phase 2 first patient dosed; IND plans: RMC-6236 & RMC-6291 H1 2022, RMC-9805 H1 2023, RMC-8839 H2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.